INTRODUCTION
============

Esophageal squamous cell carcinoma (ESCC), one of the most aggressive digestive system tumors, is associated with numerous factors, including advanced age, achalasia, Plummer-Vinson syndrome, low socioeconomic status, high-starch diets lacking in fruits and vegetables, alcohol abuse, tobacco use, previous head and neck squamous cell carcinoma, and radiation therapy [@b1-cln_72p150]. It is also an important cause of mortality in the Asian esophageal cancer belt and in the eastern part of Turkey [@b2-cln_72p150].

Helicobacter pylori (HP), a gram-negative bacterium found on the gastric mucosa, was first isolated 30 years ago [@b3-cln_72p150]. Infection with HP is one cause of duodenal or gastric ulcers (reported to develop in 1 to 10% of infected patients), gastric cancer (in 0.1 to 3%), and gastric mucosa-associated lymphoid-tissue (MALT) lymphoma (in \<0.01%) [@b4-cln_72p150]. Recent studies have demonstrated a high frequency of HP infection in gastric cancer patients, suggesting that presence of HP may function as a driver of the events contributing to oncogenesis in gastric adenocarcinomas [@b5-cln_72p150],[@b6-cln_72p150]. Furthermore, an inverse association has been established between Cag A-positive HP infection and the risk of esophageal adenocarcinoma [@b7-cln_72p150]. HP infection plays crucial roles in gastric carcinogenesis; however, the impact of HP on ESCC is not well understood.

The available data, derived from studies using serologic tests, are conflicting with respect to any association between HP and ESCC [@b8-cln_72p150]-[@b10-cln_72p150]. The aim of the present study was to examine the potential correlation between ESCC and HP infection and to compare the presence of HP in naive ESCC patients and their esophagectomized counterparts.

PATIENTS AND METHODS
====================

This retrospective trial was conducted at a university medical center in a large metropolitan area near the Iranian border of Turkey, where both ESCC and HP infection are endemic. In total, 95 ESCC patients (65 women, aged 32-92 years) were evaluated in our clinic from July 2012 to July 2015. All the patients were diagnosed with ESCC based on established endoscopic and histopathological criteria. Of these, 39 had undergone a subtotal esophagectomy. In this esophagectomy group, esophageal reconstruction was performed through a subcutaneous route in 10 patients, through a retrosternal route in 25, and through a posterior mediastinal route in 4. The reconstructed esophagus was a wide gastric tube, as described by Holscher [@b11-cln_72p150].

Postoperatively, the patients typically underwent upper gastrointestinal endoscopy 6 weeks after surgery to determine the presence or absence of HP infection.

Gastric biopsy samples were tested for urease activity using a commercial Hp-fast test kit (GI Supply®, Camp Hill, PA, USA) consisting of a urea-containing medium and a power of hydrogen (pH) detection reagent.

The control group comprised 151 dyspeptic subjects (100 women and 51 men, aged 30--85 years). Controls were also required to be medical-treatment free for at least 6 months from the time of study entry. Antrum biopsies with normal endoscopic evaluations were examined for HP using the same method. The prognostic values of the presence of HP and other clinicopathologic factors were also evaluated.

Statistical analysis
--------------------

The two groups were compared using the Mann-Whitney U-test. The differences were considered statistically significant at *p*\<0.005.

RESULTS
=======

The mean age was 52.96±11.81 years in the control group (100 women), 59.53±13.93 years in the naive ESCC group (36 females), and 55.95±11.53 years in esophagectomized group (28 females). Nearly two-thirds of the ESCC patients were female. Descriptive statistics and comparison results according to the presence of HP are shown in [Table 1](#t1-cln_72p150){ref-type="table"}.

HP infection was observed in 39 (68.4%) of the 57 naive ESCC patients, 27 (69.2%) of the 39 esophagectomized patients, and 128 (85%) of the 151 dyspeptic control patients ([Figure 2](#f2-cln_72p150){ref-type="fig"}). We found a significantly lower rate of HP in patients with ESCC compared with the dyspeptic subjects (*p*\<0.0001), whereas no statistically significant difference was detected between the naive ESCC patients and their esophagectomized counterparts (*p*\>0.005). We also found no gender differences between the groups (*p*\>0.0005).

Significantly higher levels of leukocytes and serum globulin were also found in the ESCC patients diagnosed with HP compared with those without HP infection (*p*=0.023 for leukocytes and *p*=0.045 for serum globulin).

DISCUSSION
==========

Our study revealed a strong association between HP infection and a reduced risk of ESCC. In the Turkish adult population, the prevalence of HP infection is higher than reported in Western countries. A previous investigation of 4622 Turkish subjects indicated an HP infection prevalence of 82.5% [@b12-cln_72p150]. The prevalence of HP infection in the present study was similar (85%). Squamous cell carcinomas are usually detected in the proximal two-thirds of the esophagus. They predominantly affect elderly people and usually present as dysphagia, odynophagia, and unintentional weight loss [@b13-cln_72p150]. Worldwide, esophageal cancer ranks fifth in mortality among all malignancies, and ESCC remains the most common type.

In Asia, upper gastrointestinal cancers constitute a major group of malignancies with high rates of morbidity and mortality. The esophageal cancer belt, originating in the Far East and extending through middle Asia and the Near East, encompasses many countries, including northern China, northern Iran and the eastern part of Turkey [@b14-cln_72p150]. The predominant histopathological type of esophageal cancer is the squamous cell type in the endemic Asian regions, with incidence rates that may vary 200-fold among different populations within the same defined region due to cultural practices. More than 80% of ESCC patients in the rural areas of Asia also present at advanced stages that are not amenable to curative therapies; hence the need for novel preventive strategies is urgent [@b15-cln_72p150].

The Van region of eastern Turkey is located in the western end of the esophageal cancer belt. Esophageal and gastric cancers are the most prevalent malignancies in both females and males in eastern part of Turkey [@b16-cln_72p150]. The probable culprit factors for ESCC in this region are low educational and socioeconomic status; the consumption of smoked, salted, hot, fatty foods; overconsumption of hot tea; cigarette smoking; poor intake of fresh fruits and vegetables, and poor hygienic conditions [@b17-cln_72p150]. Previous studies have shown that the eastern part of Turkey has one of the highest rates of both ESCC and HP infection. An HP infection rate of 36% was reported for gastric biopsy specimens in patients with gastric carcinoma from the Van region [@b18-cln_72p150].

Various environmental factors, including cigarette smoking and excessive alcohol intake, can be associated with an increased risk of developing ESCC [@b19-cln_72p150]. HP is considered one of the most important human carcinogens for the upper gastrointestinal tract and the stomach [@b20-cln_72p150]. At present, a few reports have indicated a possible relationship between HP and ESCC, but most of these were performed using non-endoscopic (serologic) techniques [@b7-cln_72p150]. A recent Chinese study reported an HP seropositivity of 35.3% in ESCC patients, which was lower than that of the control groups (40% and 59%) [@b21-cln_72p150]. A recent meta-analysis also found an association between CagA-negative HP strains and a marginally significant increased risk of ESCC [@b7-cln_72p150]. In contrast, a prospective and serological study from China showed no association between HP and ESCC [@b22-cln_72p150]. Another recent meta-analysis from China showed an association between HP infection and a decreased risk of ESCC in Eastern populations and a decreased risk of esophageal adenocarcinoma (EAC) in the overall population [@b23-cln_72p150].

The current study revealed no association between HP infection and ESCC among people living in the eastern part of Turkey. The low prevalence of HP in these ESCC patients was similar to that reported in the Chinese meta-analyses. We also found a predominance of ESCC in female patients, in agreement with a previous Turkish study [@b17-cln_72p150]. This phenomenon has been linked to the use of the traditional large ovens (tandirs) that use smoke to cook meals ([Figure 1](#f1-cln_72p150){ref-type="fig"}). The mechanisms by which these ovens induce esophageal carcinogenesis remain undefined, but previous work suggests that smoke may play role similar to that of cigarette smoking [@b17-cln_72p150]. We conclude that an effective follow-up strategy for HP-negative female Asian adults will be necessary if ESCC screening is to yield public health benefits. The higher levels of leucocytes and serum globulin among ESCC patients with HP may also reflect an emerging phenomenon that requires additional investigation to determine the underlying causative factors.

The H. pylori-fast test (Hp-fast test) is based on the detection of HP urease activity and has a high sensitivity (85%) and specificity (\>95%) for detecting HP infection. As this test is considered cost-effective and suitable for endoscopy units [@b24-cln_72p150], we used the Hp-fast test to establish HP infection.

The current data are limited regarding any changes in the prevalence of HP in patients who have undergone esophagectomy. We therefore performed gastroduodenoscopy with pathological examination of the biopsy specimens obtained from the gastric conduit. We observed that the rate of HP infection was lower in esophagectomized ESCC patients than in the control subjects (19% and 78%, respectively; *p*\<0.001). The rate of HP infection was similar, however, between the naive ESCC patients and the esophagectomized patients (*p*\>0.005). A Japanese study reported that the HP infection status changed from preoperatively positive to postoperatively negative and that this changing pattern was linked to the eradication of HP via the perioperative administration of antibiotics [@b25-cln_72p150]. Conversely, a report from China showed a low incidence of HP infection in the gastric conduit in patients who underwent esophagectomy, pyloroplasty, and reconstruction. The authors of that study concluded that this phenomenon was mostly due to the chronic reflux of bile after pyloroplasty [@b26-cln_72p150].

Our findings were in concordance with previous reports on HP status and gastric tube cancer patients. In our Turkish population, HP infection was not associated with ESCC and had a similar pattern to that reported for Asian populations. HP infection may not contribute to the development of ESCC in patients who reside in rural areas of Asia, especially not in females. Furthermore, esophageal damage could be diminished by the prior presence of HP in areas with a high risk of ESCC. HP treatment has been associated with improved thrombocyte levels. An increase in platelet counts was observed in only 6.7% of treated patients. In the current study, we found no relationship between HP status and thrombocyte levels [@b27-cln_72p150],[@b28-cln_72p150].

Finally, further studies are needed to address the impact of HP infection on ESCC and its natural history.
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###### 

Descriptive statistics and comparison results according to Helicobacter pylori status.

                                                               HP[1](#tfn2-cln_72p150){ref-type="table-fn"}   n    Mean      Std. Dev   Min.     Max.      *p*
  ------------------------------------------------------------ ---------------------------------------------- ---- --------- ---------- -------- --------- -------
  Age (years)                                                  \+                                             65   57.02     11.514     32       92        0.239
                                                               \-                                             30   60.43     15.939     23       87        
                                                               Total                                          95   58.09     13.084     23       92        
  Hemoglobin (gr/dL)                                           \+                                             63   12.50     2.025      8        17        0.371
                                                               \-                                             30   12.11     1.876      9        17        
                                                               Total                                          93   12.38     1.976      8        17        
  Hematocrit                                                   \+                                             63   37.20     5.616      24       49        0.427
                                                               \-                                             30   36.21     5.502      28       49        
                                                               Total                                          93   36.88     5.569      24       49        
  Leukocytes (/mm[3](#tfn4-cln_72p150){ref-type="table-fn"})   \+                                             63   7.598     3.8817     1.8      25.0      0.023
                                                               \-                                             30   5.803     2.4689     2.0      11.0      
                                                               Total                                          93   7.019     3.5760     1.8      25.0      
  Platelets (/mm[3](#tfn4-cln_72p150){ref-type="table-fn"})    \+                                             63   270.000   123.839    67.000   702.000   0.150
                                                               \-                                             30   616.687   324.542    79.000   178.000   
                                                               Total                                          93   443.343   184.309    67.000   178.000   
  ALT[2](#tfn3-cln_72p150){ref-type="table-fn"} (U/L)          \+                                             63   18.94     17.766     6        142       0.284
                                                               \-                                             30   15.27     8.026      6        39        
                                                               Total                                          93   17.75     15.362     6        142       
  AST[3](#tfn4-cln_72p150){ref-type="table-fn"} (U/L)          \+                                             62   33.02     48.837     2        341       0.089
                                                               \-                                             30   17.57     6.976      9        38        
                                                               Total                                          92   27.98     40.833     2        341       
  Albumin (g/dL)                                               \+                                             58   3.71      0.734      2        5         0.882
                                                               \-                                             25   3.69      0.667      2        5         
                                                               Total                                          83   3.71      0.711      2        5         
  Globulin (g/dL)                                              \+                                             47   3.07      0.533      2        4         0.045
                                                               \-                                             19   2.73      0.772      1        4         
                                                               Total                                          66   2.97      0.625      1        4         
  Calcium (mg/dL)                                              \+                                             57   8.92      1.362      1        13        0.370
                                                               \-                                             27   9.17      0.639      8        11        
                                                               Total                                          84   9.00      1.181      1        13        

**Std. Dev: Standard deviation**
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